Risk of highly resistant bacteria importation from repatriates and travelers hospitalized in foreign countries: About the French recommendations to limit their spread

Journal of Travel Medicine

Volumn 18, Issue 5, 2011, Pages 344-351

  Lepelletier, Didier ^a,b   Andremont, Antoine ^c,d   Grandbastien, Bruno ^e  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; EXTENDED SPECTRUM BETA LACTAMASE; METALLO BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL SPREAD; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; ENTEROBACTERIACEAE; FRANCE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRACTICE GUIDELINE; REVIEW; TRAVEL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BACTERIA; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, BACTERIAL; EMIGRATION AND IMMIGRATION; FRANCE; HUMANS; INCIDENCE; INFECTION; PRACTICE GUIDELINES AS TOPIC; TRAVEL;

EID: 80052427138     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2011.00547.x     Document Type: Review

References (67)

1. Falagas ME, Karageorgopoulos DE., Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008; 46: 1121-1122.
2. Souli M, Galani I, Giamarellou H., Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008; 13: 1-11.
3. Magiorakos AP, Srinivasan A, Carey RB., Multidrug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. (Accepted). doi: 10.1111/j.1469-0691.2011.03570.x.
4. Livermore DM., Has the era of untreatable infections arrived. J Antimicrob Chemother 2009; 64 (Suppl 1): i29-i36
5. American Society for Microbiology. Antibiotic resistance: an ecological perspective on an old problem. 2009. Available at:. (Accessed 2011 May).
6. Institut national de la statistique et des études économiques (INSEE). 2007. Available at
7. Ministère des Affaires Etrangères. 2008. Available at:. (Accessed 2010 Sep).
8. Coignard B, Barbut F, Blanckaert K, et al., Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006. Euro Surveill 2006; 11: E060914.1.
9. Birgand G, Blanckaert K, Carbonne A, et al., Investigation of a large outbreak of Clostridium difficile PCR-ribotype 027 infections in northern France, 2006-2007 and associated clusters in 2008-2009. Euro Surveill 2010; 15: pii.19597.
10. Naas T, Nordmann P, Vedel G, Poyart C., Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49: 4423-4424.
11. Carbonne A, Thiolet JM, Fournier S, et al., Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro Surveill 2010; 15:pii: 19734.
12. Vaux S, Carbonne A, Thiolet JM, et al., Emergence of carbapenemase- producing Enterobacteriaceae in France, 2004 to 2011. Euro Surveill 2011; 16:pii: 19880.
13. Lucet JC, Armand-Lefrevre Laurichesse JJ, et al., Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect 2007; 67: 42-48.
14. Aumeran C, Baud O, Lesens O, et al., Successful control of a hospital-wide vancomycin-resistant Enterococcus faecium outbreak in France. Eur J Clin Microbiol Infect Dis 2008; 27: 1061-1064.
15. Naas T, Coignard B, Carbonne A, et al., VEB-1 extended-spectrum β-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis 2006; 12: 1214-1222.
16. Haut Conseil de la Santé publique. Commission spé cialisée Sécurité des patients: infections nosocomiales et autres évènements indésirables liés aux soins et aux pratiques. Recommandations pour le dépistage du portage digestif des bactéries commensales multi-résistantes aux antibiotiques importées en France à l'occasion du rapatriement de patients en provenance de l'étranger et ma±trise de leur diffusion. 2010. Available at:. (Accessed 2011 May).
17. Nordmann P, Cuzon G, Naas T., The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-236.
18. Oteo J, Perez-Vasquez M, Campos J., Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010; 23: 320-326.
19. Livermore DM, Woodford N., The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-420.
20. Cornaglia G, Akova M, Amicosante G, et al., Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29: 380-388.
21. Yong D, Toleman MA, Giske CG, et al., Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-5054.
22. Yigit H, Queenan AM, Anderson GJ, et al., Novel carbapenem-hydrolyzing β-lactamase KPC-1 from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-1161.
23. Kitchel B, Rasheed JK, Patel JB, et al., Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258 Antimicrob Agents Chemother. 2009; 53: 3365-3370.
24. Leavitt A, Navon-Venezia S, Chmelnitsky I, et al., Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51: 3026-3029.
25. Woodford N, Zhang J, Warner M, et al., Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008; 62: 1261-1264.
26. Giakoupi P, Maltezou H, Polemis M, et al., KPC-2-producing Klebsiella pneumonia infections in Greek hospitals are mainly a hyperepidemic clone. Euro Surveill 2009; 14:pii: 19218.
27. Dortet L, Radu I, Gautier V, et al., Intercontinental travel of patients and dissemination of plasmid-mediated carbapenemase KPC-3 associated with OXA-9 and TEM-1. J Antimicrob Chemother 2008; 61: 455-457.
28. Cuzon G, Naas T, Demachy MC, Nordmann P., Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother 2008; 52: 796-797.
29. Decre D, Birgand G, Geneste D, et al., Possible importation and subsequent cross-transmission of OXA-48-producing Klebsiella pneumoniae, France, 2010. Euro Surveill 2010; 15:pii: 19718.
30. European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial Resistance Surveillance in Europe. Available at:. (Accessed 2011 Feb).
31. Kamarasamy K, Toleman MA, Walsh TR, et al., Emergence of a new antibiotic resistance in India, Pakistan, and the UK: a prospective survey. Lancet Infect Dis 2010; 10: 597-602.
32. Livermore DM, Walsh TR, Toleman MA, Woodford N., Balkan NDM-1: escape or transplant? Lancet Infect Dis 2011; 11: 164.
33. Walsh TR, Livermore DM, Toleman MA., Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human: an environmental point prevalence study. Lancet Infect Dis 2011; 11: 355-362.
34. Werner G, Coque TM, Hammerum AM, et al., Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008; 13:pii: 19046.
35. Sievert DM, Rudrik JT, Patel JB, et al., Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46: 668-674.
36. Deshpande LM, Fritsche TR, Moet GJ, et al., Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbial Infect Dis 2007; 58: 163-170.
37. McGowan JE., Debate-guidelines for control of glycopeptide-resistant enterococci (GRE) have not yet worked. J Hosp Infect 2004; 57: 281-284.
38. Bourdon N, Fines-Guyon M, et al., Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother 2011; 66: 713-721.
39. Lucet JC, Andremont A, Coignard B., Les entérocoques résistants aux glycopeptides (ERG): Glycopeptide-resistant enterococci (GRE): epidemiological situation, current control measures and future challenge. Bull Epidemiol Hebd 2008; 41-42: 386-390.
40. Haut Conseil de la Santé Publique. Rapport relatif à la ma±trise de l'émergence et de la diffusion des ERG dans les établissements de santé. 2010. Available at:. (Accessed 2011 Jan).
41. Peleg AY, Seifert H, Paterson DL., Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbial Rev 2008; 21: 538-582.
42. Towner KJ., Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73: 355-363.
43. U̧kay I, Sax H, Harbarth S, et al., Multi-resistant infections in repatriated patients after natural disasters: lessons learned from the 2004 tsunami for hospital infection control. J Hosp Infect 2008; 68: 1-8.
44. Calhoun JH, Murray CK, Manring MM., Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res 2008; 466: 1356-1362.
45. Tien HC, Battad A, Bryce EA, et al., Multi-drug resistant Acinetobacter infections in critically injured Canadian forces soldiers. BMC Infect Dis 2007; 7: 95.
46. Davis KA, Moran KA, McAllister CK, Gray PJ., Multidrug-resistant Acinetobacter extremely infections in soldiers. Emerg Infect Dis 2005; 11: 1218-1224.
47. Griffith ME, Lazarus DR, Mann PB, et al., Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol 2007; 28: 720-722.
48. Cross-contamination prevention: additional contact precautions. National guidelines 2009. French Society for Hospital Hygiene. 2009. Available at:.
49. Circulaire N°DGS/RI/DGOS/PF/2010/413 du 6 décembre 2010: relative à la mise en æuvre de mesures de contrÔles des cas importés d'entérobactéries productrices de carbapénèmases (EPC).
50. Soto SM., Human migration and infectious diseases. Clin Microbial Infect 2009; 15 (Suppl 1): 26-28.
51. Arguin PM, Marano N, Freedman DO., Globally mobile populations and the spread of emerging pathogens. Emerg Infect Dis 2009; 15: 1713-1714.
52. Gushulak B, Funk M, Steffen R., Global changes related to travelers' health. J Travel Med 2007; 14: 205-208.
53. Steffen R, Amitirigala I, Mutsch M., Health risks among travelers-need for regular updates. J Travel Med 2008; 15: 145-146.
54. Hawkey PM, Jones AM., The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 (Suppl 1): i3-i10.
55. MacPherson DW, Gushulak BD, Bala S, et al., Population mobility, globalization, and antimicrobial drug resistance. Emerg Infect Dis 2009; 15: 1727-1732.
56. Fisher D, Vedman A, Diefenbach M, Shäfer V., Bacterial colonization of patients undergoing international air transport: a propsective epidemiologic study. J Travel Med 2004; 11: 44-48.
57. Kaiser AM, Schultsz C, Kruithof GJ, et al., Carriage of resistant microorganisms in repatriates from foreign hospitals to the Netherlands. Clin Microbiol Infect 2004; 10: 972-979.
58. Steffen R, Rickenbach M, Wilhelm U, et al., Health problems after travel to developing countries. J Infect Dis 1987; 156: 84-91.
59. Hill DR., Health problems in a large cohort of Americans travelling to developing countries. J Travel Med 2000; 7: 259-266.
60. CDC. Detection of Enterobacteriaceae isolates carrying metallo-betalactamase-United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 750.
61. Leverstein-Van Hall MA, Stuart JC, Voets GM, et al., Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect Dis 2010; 10: 830-831.
62. Pitout JD., The latest threat in the war on antimicrobial resistance. Lancet Infect Dis 2010; 10: 578-579.
63. Wise R, Piddock L., The need for new antibiotics. Lancet 2010; 375: 638.
64. Grundmann H, Livermore DM, Giske CG, et al., Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15:pii: 19711.
65. Comité sur les infections nosocomiales du Québec. Institut National de Santé Publique du Québec. Avis et recommandations: Prévention et contrÔle de la transmission des enté robactéries productrices de carbapénèmases dans les milieux de soins aigus du Québec. Octobre 2010. Available at:. (Accessed 2011 May).
66. Kluytmans-Vanderbergh MF, Kluytmans JA, Voss A., Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection 2005; 33: 309-313.
67. Wernli D, Haustein T, Conly J, et al., A call for action: the application of the international health regulations to the global threat of antimicrobial resistance. PLoS Med 2011; 8: e1001022.